Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1662-1672

  Ravindranathan, Krishna P ^a   Mandiyan, Valsan ^b   Ekkati, Anil R ^a   Bae, Jae H ^b   Schlessinger, Joseph ^b   Jorgensen, William L ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG STRUCTURE; IC 50;

ADENOSINE TRIPHOSPHATE; BINDING SITES; DATABASES, FACTUAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; LIBRARIES, DIGITAL; MODELS, MOLECULAR; MONTE CARLO METHOD; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649196704     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901386e     Document Type: Article

References (65)

1. Bishop, J. M. The molecular genetics of cancer. Science 1987, 235, 305-311.
2. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212. (Pubitemid 20149352)
3. Aaronson, A. S. Growth factors and cancer. Science 1991, 254, 1146-1153.
4. Jaye, M.; Schlessinger, J.; Dionne, C. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and, signal transduction. Biochim. Biophys. Acta 1992, 1135, 185-199.
5. Basilico, C.; Moscatelli, D. The Fgf Family of Growth, Factors and Oncogenes. Adv. Cancer. 1992, 59,115-165.
6. Schlessinger. J. Cell Signaling by Receptor Tyrosine Kinases. Cell 2000, 103, 211-225.
7. Klagsbrun, M.; Edelman, E. R. Biological and biochemical properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis. Arteriosclerosis 1989, 9, 269-278.
8. Brem, H.; Klagsbrun, M. Oncogenes and Tumor Suppressor Genes. In Human Malignancies; Benz, C. C., Liu, E. T., Eds.; Kluwer Academic: Boston, 1993; pp 211-231.
9. Klagsbrun, M.; D'Amore, P. A. Regulators of Angiogenesis. Annu. Rev.Physiol 1991, 53, 217-239.
10. Adnane, J.; Gaudray, P.; Dionne, C. A.; Crumley, G.; Jaye, M.; Schlessinger, J.; Jeanteur, P.; Birnbaum, D.; Theillet, C. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncozene 1991, 6, 659-663.
11. Penault-Llorca, F.; Bertucci, F.; Adélaïde, J.; Pare, P.; Coulier, F.; Jacquemier, J.; Birnbaum, D.; Delapeyrière, O. Expression of fgf and fgf receptor genes in human breast cancer. Int. J. Cancer 1995, 61, 170-176.
12. Jacquemier, J.; Adelaide, J.; Parc, P.; Penault-Llorca, F.; Planche, J.; Delapeyriere, O.; Birnbaum, D. Expression of the FGFRl gene in human breast-carcinoma cells. Int. J. Cancer 1994, 59,373-378. (Pubitemid 24331829)
13. McLeskey, S. W.; Ding, I. Y.; Lippman, M. E.; Kern, F. G. MDAMB-134 breast carcinoma cells overexpress fibroblast growth, factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res.-1994, 54, 523-530.
14. Luqmani, Y. A.; Mortimer, C.; Yiangou, C.; Johnston, C. L.; Bansal, G. S.; Sinnett, D. S.; Law, M.; Coombes, R. C. Expression, of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int, J. 1995, 64, 274-279.
15. Jaakkola, S.; Salmikangas, P.; Nylund, S.; Partanen, J.; Armstrong, E.; Pyrhönen, S.; Lehtovirta, P.; Nevanlinna, H. Amplification of FGFR4 gene in, human breast and gynecological cancers. Int. J. Cancer 1993, 54, 378-382 (Pubitemid 23169673)
16. Leung, H. Y.; Gullick, W. J.; Lemoine, N. R. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer Int. J.Cancer 1994, 59, 667-675. (Pubitemid 24358591)
17. Yamaguchi, F.; Saya, H.; Bruner, J. M.; Morrison, R. S. Differential expression, of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc. Natl. Acad. Sci U.S.A. 1994, 91, 484-488.
18. Morrison, R. S.; Yamaguchi, F.; Saya, H.; Bruner, J. M.; Yahanda, A. M.; Donehower, L. A.; Berger, M. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. Neuro-Oncol. 1994, 18, 207-216. (Pubitemid 24209422)
19. Myoken, Y.; Myoken, Y.; Okamoto, T.; Kan, M.; McKeehan, W. L.; Sato, J. D.; Takada, K. Expression of fibroblast growth factor-1 (FGF-I), FGF-2 and FGF receptor-1 in a human salivary-gland adenocarcinoma cell line: evidence of autocrine growth. Int. J. Cancer 1996, 65, 650-657. (Pubitemid 26092294)
20. Li, J. J.; Huang, Y. Q.; Moscatelli, D.; Nicolaides, A.; Zhang, W. C.; Friedman-Kien, A. E. Expression, of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived, cells. Cancer 1993, 72, 2253-2259.
21. Theillet, C.; Adelaide, J.; Louason, G.; Bonnet-Dorion, F.; Jacquemier, J.; Adnane, J.; Longy, M.; Katsaros, D.; Sismondi, P.; Gaudray, P.; Birnbaum, D. FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers. Genes Chormosomes Cancer 1993, 7, 219-226.
22. Story, M. T. Regulation of prostate growth by fibroblast growth factors. World J., Urol. 1995, 13, 297-305.
23. Ware, J. L. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev. 1993, 12, 287-301.
24. Reardon, W.; Winter, R. M.; Rutland, P.; Pulleyn, L. J.; Jones, B. M.; Malcolm, S. Mutations in, the fibroblast growth, factor receptor 2 gene cause Crouzon syndrome. Nat. Genet. 1992, 8, 98-103. (Pubitemid 24274068)
25. Neilson, K. M.; Friesel, R. E. Constitutive Activation of Fibroblast Growth Factor Receptor-2 by a Point Mutation, Associated with, Crouzon Syndrome. J. Biol Chem. 1995, 270, 26037-26040.
26. Shiang, R.; Thompson, L. M.; Zhu, Y. Z.; Church, D. M.; Fielder, T. J.; Bocian, M.; Winokur, S. T.; Wasmuth, J. J. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form, of dwarfism, achondroplasia. Cell 1994, 78, 335-342.
27. Rousseau, F.; Bonaventure, J.; Legeai-Mallet, L.; Pelet, A.; Rozet, J.; Maroteaux, P.; Le Merrer, M.; Munnich, A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994, 371, 252-254. (Pubitemid 24293024)
28. Webster, M. K.; Donoghue, D. J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 1996, 15, 520-527. (Pubitemid 26044565)
29. Naski, M. C.; Wang, Q.; Xu, J.; Ornitz, D. M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and, thanatophoric dysplasia. Nat. Genet 1996, 13, 233-237. (Pubitemid 26166160)
30. Tavormina, P. L.; Shiang, R.; Thompson, L. M.; Zhu, Y. Z.; Wilkin, D. J.; Lachman, R. S.; Wilcox, W. R.; Rimoin, D. L.; Colin, D. H.; Wasmuth, J. J. Thanatophoric dysplasia (types I and II) caused, by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet 1995, 9, 321-328.
31. Webster, M. K.; D'Avis, P. Y.; Robertson, S. C.; Donoghue, D. J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 1996, 16, 4081-4087.
32. Mohammadi, M.; McMahon, G.; Sun, Li; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science 1997, 276, 955-960. (Pubitemid 27209095)
33. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17, 5896-5904. (Pubitemid 28474784)
34. Noble, M. E. M.; Endicott, J. A.; Johnson, L. N. Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science 2004, 303, 1800-1805. (Pubitemid 38374863)
35. Liao, J. J.-L. Molecular Recognition, of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors. J. Med. 2007, 50,409-424 (Pubitemid 46239775)
36. Manning, G;Whyte, D. B.; Martinez, R.; Hunter,T.; Sudarsanam, S. The Protein Kinase Complement of the Human Genome. Science 2002, 298,1912-1934. (Pubitemid 35425239)
37. (a) Hamby, J. M.; Connolly, C. J. C.; Schroeder, M. C.; Winters. R. T.; Showalter, H. D. H.; Panek, R. L.; Major, T. C.; Olsewski, B.; Ryan, M. J.; Dahring, T.; Lu, G. H.; Keiser, J.; Amar, A.; Shen, C.; Kraker, A. J.; Slintak, V.; Nelson, J. M.; Fry, D. W.; Bradford, L.; Hallak, H.; Doherty, A. M. Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors. ,J, Md, Chem. 1997, 40, 2296-2303. (Pubitemid 27342564)
38. (b) Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Showalter, H. D. Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
39. Thompson, A.M.;Connolly,C. J.C.; Hamby, J. M.; Boushelle, S.; Hartl, B. G.; Amar, A. M.; Kraker, A. J.; Driscoll, D. L.; Steinkampf. R. W.; Patmore. S. J.; Vincent. P. W.; Roberts. B. J.; Elliott, W. L; Klohs, W.; Leopold, W. R.; Showalter, H. D. H; Denny, W. A. 3-(3,5-Dimethoxyphenyl)-l,6-naphthyridine-2, 7diamines and Related, 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase. J. Med. Chem. 2000, 43, 4200-4211.
40. (a) Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
41. (b) Kumar, R.; Crouthamel, M.-C; Rominger, D. H.; Gontarek, R. R.; Tummino, P. J.; Levin, R. A.; King, A. G. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 2009, 101, 1717-1723.
42. Bae, J. H.; Ravindranathan, K. P.; Ma.nd.iyan V.; Ekkati, A. R.; Schiessinger, J.; Jorgensen, W. L. Protein Data Bank ID 3JS2.
43. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182
44. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Md. Chem. 2004, 47, 1739-1749. (Pubitemid 38380917)
45. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. J. Med Chem- 2006, 49, 6177-6196.
46. (a) Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and. testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am, Chem. Soc. 1996, 118, 11225-11236. (Pubitemid 26399746)
47. (b) Jorgensen, W. L.; Tirado-Rives, J. Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. Proc. Nat. Acad. Sci. Sci. U.S.A., 2005, 102, 6665-6670. (Pubitemid 40675374)
48. Muegge, I.; Enyedy, I. J. Virtual Screening for Kinase Targets. Curr. Med. Chem. 2004, 11, 693-707.
49. Lyne, P. D.; Kenny, P. W.; Cosgrove, D. A.; Deng, C.; Zabludoff, S.; Wendoloski, J. J.; Ashwell, S. Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge based Virtual Screening. J. Med. Chem. 2004, 47, 1962-1968. (Pubitemid 38453915)
50. Singh, J.; Chuaqui, C. E.; Boriack-Sjodin, P. A.; Lee,W.; Pontz, T.; Corbley, M. J.; Cheung, H. K.; Arduini, R. M.; Mead, J. N.; Newman, M. N.; Papadatos, J. L.; Bowes, S.; Josiah, S.; Ling, L. E. Successful Shape Based, Virtual Screening: The Discovery of a Potent Inhibitor of the Type I TGF B Receptor Kinase (TBRl). Bioorgs. Med Chem. Lett- 2003, 13, 4355-4359.
51. Manetti, F.; Botta, M. Small-Molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK). Curr. Pharm, Des. 2003, 9, 567-581. (Pubitemid 36221724)
52. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the Epidermal Growth, Factor Receptor 2 Kinase Domain Alone and in Complex with 3,4-Anilioquinazoline Inhibitor. J. Biol, Chem. 2002, 277, 46265-46272. (Pubitemid 35417619)
53. Hubbard, S. R. Crystal structure of the activated insulin, 2 receptor tyrosine kinase in complex with peptide 3 substrate and ATP analog. EMBO J. 1997, 16, 5572-5582.
54. Hasegawa, M.; Nishigaki, N.; Washio, Y.; Kano, K.; Harris, P. A.; Sato, H.; Mori, I.; West, R. I.; Shibahara, M.; Toyoda, H.; Wand, L.; Nolte, R. T.; Veal, J. M.; Cheung, M. Discovery of Novel Benzimadazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors. J. Med. Chem. 2007, 50, 4453-4470. (Pubitemid 47378842)
55. Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-Van der Brempt, C.; Morgentin, R.; Norman, R. A.; Oliver, A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. N-(5-Chloro-l,3-benzodioxol- 4-yl)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy) quinazolin4-amine, a novel, highly selective, orally available, dual-specific c-src/abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465-6488.
56. Wang, Z.; Canagarajah, J .;Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural Basis of Inhibitor Selectivity in Map Kinases. Structure 1998, 6, 1117-1128.
57. Jorgensen, W. L.; Tirado-Rives, J. Molecular Modeling of Organic and Biomolecular Systems using BOSS and MCPRO. J. Comput. Chem. 2005, 26, 1689-1700. (Pubitemid 43076181)
58. Furdui, C. M.; Lew, E. D.; Schlessinger, J.; Anderson, K. S. Autophosphorylation of FGFR1 Kinase is Mediated, by a Sequential and Precisely Ordered, Reaction. Mol. Cell 2006, 21, 711-717.
59. Mohammadi, M.; Schlessinger, J.; Hubbard, S. R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996, 86, 577-587.
60. Nichols, S. E.; Domaoal, R. A.; Thakur, V. V.; Bailey, C. M.; Wang, L.; Tirado-Rives, J.; Anderson, K. S.; Jorgensen, W. L. Discovery of Wild-type and Y181C Mutant Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Using Virtual Screening with Multiple Protein Structures. J. Chem. Inf. Model- 2009, 49, 1272-1279.
61. Barreiro, G.; Kim, J. T.; Guimarães, C. R. W.; Bailey, C. M.; Domaoal, R. A.; Wang, L.; Anderson, K. S.; Jorgensen, W. L. From Docking False-Positive to Active Anti-HIV Agent. J. Med. Chem. 2007, 50, 5324-5329. (Pubitemid 350057844)
62. Jorgensen, W. L. Efficient Drug Lead, Discovery and Optimization. Acc. Chem. Res. 2009, 42, 724-733.
63. Jorgensen, W. L. QikProp, version 3.0; Schrodinger, LLC: New York, 2006.
64. Thakur, V. V.; Kim, J. T.; Hamilton, A. D.; Bailey, C. M.; Domaoal, R. A.; Wang, L.; Anderson, K. S.; Jorgensen, W. L. Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2006,16, 5664-5667. (Pubitemid 44415430)
65. Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Prediction of Protein-Ligand Interactions. Docking and Scoring: Successes and Gaps. J.Med. Chem. 2006, 5851-5855.